Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma

References

• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63:8–160.
   PubMed Web of Science ®Google Scholar
• Katelaris CH, Lai CK, Rhee CS, et al. Nasal allergies in the Asian-Pacific population: results from the allergies in Asia-Pacific survey. Am J Rhinol Allergy. 2011;25(Suppl 1):S3–S15.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol. 2009;124:S43–S70.
   PubMed Web of Science ®Google Scholar
• Price D, Zhang Q, Kocevar VS, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005;35:282–287.
   PubMed Web of Science ®Google Scholar
• Thomas M, Kocevar VS, Zhang Q, et al. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005;115:129–134.
   PubMed Web of Science ®Google Scholar
• Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one-airway condition. BMC Pulm Med. 2006;6(Suppl 1):S5.
   PubMedGoogle Scholar
• Corren J, Adinoff AD, Buchmeier AD, et al. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 1992;90:250–256.
   PubMed Web of Science ®Google Scholar
• Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol. 1996;98:274–282.
   PubMed Web of Science ®Google Scholar
• Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993;91:97–101.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128:1910–1920.
   PubMed Web of Science ®Google Scholar
• Dahl R, Nielsen LP, Kips J, et al. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy. 2005;60:875–881.
   PubMed Web of Science ®Google Scholar
• Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: mechanisms and applications. Clin Dev Immunol. 2012;2012:623474.
   PubMedGoogle Scholar
• National Heart, Lung, and Blood Institute Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/.
   Google Scholar
• Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA). 2017. Available from: http://www.ginasthma.org/.
   Google Scholar
• Blaiss MS, Dykewicz MS, Skoner DP, et al. Diagnosis and treatment of nasal and ocular allergies: the allergies, immunotherapy, and rhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol. 2014;112:322–8 e1.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Stadler E, Kuster D, et al. Medical care and treatment of allergic rhinitis: a population-based cohort study based on routine healthcare utilization data. Allergy. 2016;71:850–858.
   PubMed Web of Science ®Google Scholar
• Fromer LM, Blaiss MS, Jacob-Nara JA, et al. Current Allergic Rhinitis Experiences Survey (CARES): consumers’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35:307–315.
   PubMed Web of Science ®Google Scholar
• Devillier P, Dreyfus JF, Demoly P, et al. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.
   PubMed Web of Science ®Google Scholar
• Matricardi PM, Kuna P, Panetta V, et al. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol. 2011;128(791–9):e6.
   Google Scholar
• Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116:338–344.
   PubMed Web of Science ®Google Scholar
• Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol. 2016;138:1081–1088.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? the Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844.
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–50.e4.
   PubMed Web of Science ®Google Scholar
• Phillips K, Oborne J, Lewis S, et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax. 2004;59:26–30.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Allergen immunotherapy: what’s new, what’s next? Expert Rev Clin Immunol. 2015;11:959–961.
   PubMed Web of Science ®Google Scholar
• Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(150–6):e1–5.
   Google Scholar
• Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol. 2011;127:974-81 e1-7.
   Web of Science ®Google Scholar
• Creticos P, Esch R, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2013;133:751–758.
   PubMed Web of Science ®Google Scholar
• Esch RE, Bush RK, Peden D, et al. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;100:475–481.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Oppenheimer J, Vatsia GA, et al. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1993;92:229–236.
   PubMed Web of Science ®Google Scholar
• Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125:660–666.
   PubMed Web of Science ®Google Scholar
• Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130:215–24 e7.
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133:1608–14.e6.
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64–71 e4.
   PubMed Web of Science ®Google Scholar
• Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167–73 e7.
   PubMed Web of Science ®Google Scholar
• Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130:1327–1334.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131:1342–9 e6.
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118:434–440.
   PubMed Web of Science ®Google Scholar
• Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61:185–190.
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–1345.
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809.
   PubMed Web of Science ®Google Scholar
• Maloney J, Berman G, Gagnon R, et al. Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. J Allergy Clin Immunol Pract. 2016;4:301–9 e2.
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112:146–53.e2.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134:568–75.e7.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127:72–80 e2.
   PubMed Web of Science ®Google Scholar
• Nolte H, Hebert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013;110:450–6 e4.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315:1715–1725.
   PubMed Web of Science ®Google Scholar
• Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160–6 e3.
   PubMed Web of Science ®Google Scholar
• Grastek (Timothy grass pollen allergen extract tablet for sublingual use). Full Prescribing Information, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2014.
   Google Scholar
• Oralair (Sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract tablet for sublingual use). Full Prescribing Information, Stallergenes S.A., Antony, France, 2014.
   Google Scholar
• Aasbjerg K, Backer V, Lund G, et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy. 2014;44:417–428.
   PubMed Web of Science ®Google Scholar
• Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59:45–53.
   PubMed Web of Science ®Google Scholar
• Quirino T, Iemoli E, Siciliani E, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26:1253–1261.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Carretta A, Tummolo RA, et al. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Int J Immunopathol Pharmacol. 2009;22:403–413.
   PubMed Web of Science ®Google Scholar
• Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157:288–298.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130:1097–107 e2.
   PubMed Web of Science ®Google Scholar
• Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131:1361–1366.
   PubMed Web of Science ®Google Scholar
• Nelson H, Cartier S, Allen-Ramey F, et al. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract. 2015;3:256–66 e3.
   PubMed Web of Science ®Google Scholar
• Dahl R, Roberts G, de Blic J, et al. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy Asthma Proc. 2016;37:92–104.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Epstein T, Murphy-Berendts K, et al. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol. 2010;104:530–535.
   PubMed Web of Science ®Google Scholar
• Epstein TG, Liss GM, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014;2:161–167.
   PubMed Web of Science ®Google Scholar
• Epstein TG, Liss GM, Murphy-Berendts K, et al. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008-2013). Ann Allergy Asthma Immunol. 2016;116:354–9 e2.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302–311.
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1–55.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471–7, 7 e1.
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135:1494–501 e6.
   PubMed Web of Science ®Google Scholar
• Wang DH, Chen L, Cheng L, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013;123:1334–1340.
   PubMed Web of Science ®Google Scholar
• Vaswani R, Garg A, Parikh L, et al. Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause. Ann Allergy Asthma Immunol. 2015;115:241–243.
   PubMed Web of Science ®Google Scholar
• Nolte H, Casale TB, Lockey RF, et al. Epinephrine use in clinical trials of sublingual immunotherapy tablets. J Allergy Clin Immunol: In Practice. 2017;5:84–89.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14:363–370.
   PubMed Web of Science ®Google Scholar
• Leatherman B, Skoner DP, Hadley JA, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. Int Forum Allergy Rhinol. 2014;4:779–788.
   PubMed Web of Science ®Google Scholar
• Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104:13–29.
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25 e5.
   PubMed Web of Science ®Google Scholar
• de Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma–post hoc results from a randomised trial. Respir Med. 2014;108:1430–1437.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138:1631–1638.
   PubMed Web of Science ®Google Scholar
• Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11:586–593.
   PubMed Web of Science ®Google Scholar
• Carson S, Lee N, Thakurta S. Drug class reviews. IN: Drug class review: newer antihistamines: final report update 2. Portland (OR): Oregon Health & Science University Portland; 2010. Oregon 97239. All rights reserved.
   Google Scholar
• Scadding G. Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments. Paediatr Drugs. 2008;10:151–162.
   PubMedGoogle Scholar
• Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67:887–901.
   PubMed Web of Science ®Google Scholar
• Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22:1–12.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Wines RCM, DelMonte M, et al. drug class reviews. IN: Drug class review: controller medications for asthma: final update 1 report. Portland (OR): Oregon Health & Science University; 2011. Copyright (c) 2011 by Oregon Health & Science University.
   Google Scholar
• Walters EH, Gibson PG, Lasserson TJ, et al. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev. 2007;(1):CD001385.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
   PubMed Web of Science ®Google Scholar
• Loke YK, Blanco P, Thavarajah M, et al. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. Plos One. 2015;10:e0133428.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Rev Clin Immunol. 2014;10:1437–1451.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Maloney J, Calderon M, et al. Occurrence and duration of local adverse reactions is similar for the ragweed (MK-3641), grass (MK-7243), and house dust mite (MK-8237) sublingual immunotherapy tablets and consistent with an immediate IgE-mediated reaction. Ann Allergy Asthma Immunol. 2014;113:A7.
   Web of Science ®Google Scholar
• Nolte H, Amar N, Bernstein DI, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2014;113:93–100 e3.
   PubMed Web of Science ®Google Scholar
• Oralair: Company briefing. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM377851.pdf.
   Google Scholar
• Ragwitek (short ragweed pollen allergen extract tablet for sublingual use). Full Prescribing Information, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2014.
   Google Scholar
• Grastek: Company briefing. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm378093.pdf, 2014.
   Google Scholar
• Ragwitek: Company briefing. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm382840.pdf, 2014.
   Google Scholar
• ODACTRA (House dust mite allergen extract tablet for sublingual use). Full Prescribing Information, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2017.
   Google Scholar
• Creticos PS, Bernstein DI, Casale TB, et al. Coseasonal initiation of allergen immunotherapy: a systematic review. J Allergy Clin Immunol Pract. 2016;4:1194-1204.e4.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Kleine-Tebbe J, et al. Safety of year-round initiation with SQ house dust mite sublingual immunotherapy tablet. J Allergy Clin Immunol. 2017;139:AB61.
   Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–948.
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–256.
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851–857.
   PubMed Web of Science ®Google Scholar
• Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103:451–459. quiz 9-61, 95
   PubMed Web of Science ®Google Scholar
• Nelson H, Blaiss M, Nolte H, et al. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy. 2013;68:252–255.
   PubMed Web of Science ®Google Scholar